A major wrongful death lawsuit has been filed alleging defects in Abbott Laboratories' (NYSE:ABT) FreeStyle Libre 3 and Libre 3 Plus glucose monitoring systems. The claim links the products to seven ...

Abbott Laboratories reported strong Q4 2023 earnings, with year-over-year growth in EPS and revenue. The company's 2024 guidance projects further growth and improved ...

In a decisive move to fund one of its most significant strategic acquisitions in recent years, Abbott Laboratories has launched a massive $20 billion bond offering. The proceeds are earmarked to ...

The S&P 500 has performed well in 2023, but healthcare stocks have lagged behind. Abbott Laboratories continues to lap difficult comparable quarterly earnings reports, but the core business has been ...

Abbott Laboratories ABT CEO Robert Ford, while speaking at the HLTH conference in Las Vegas, outlined the company's strategic move into the consumer wearables market. While Abbott has historically ...

Abbott Laboratories (NYSE: ABT) is a diversified health care company that gives investors a great deal of stability. Between testing, nutritional products, pharmaceuticals, and medical devices, the ...

WASHINGTON (AP) — The Food and Drug Administration said Wednesday that Abbott Laboratories is recalling up to 359 million testing strips used by diabetics because they can give falsely low blood sugar ...

On Wednesday, Abbott Laboratories (NYSE:ABT) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion. Organic sales growth for the underlying ...